Quick Answer
ADMA BIOLOGICS, INC. reported Operating Income Loss of $191.44 million for the year ending 2025.
- ADMA BIOLOGICS, INC. showed an increase of +37.7% in Operating Income Loss from 2024 to 2025.
- This data is from ADMA BIOLOGICS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ADMA BIOLOGICS, INC.'s Operating Income Loss has grown by 4,241.1%.
- Historical annual values: Fiscal year 2025: $191.44 million | Fiscal year 2024: $138.98 million | Fiscal year 2023: $21.63 million | Fiscal year 2022: -$39.37 million | Fiscal year 2021: -$58.37 million | Fiscal year 2020: -$64.91 million | Fiscal year 2019: -$41.42 million | Fiscal year 2018: -$60.29 million | Fiscal year 2017: -$39.31 million | Fiscal year 2016: -$17.33 million | Fiscal year 2015: -$15.51 million | Fiscal year 2014: -$16.02 million | Fiscal year 2013: -$15.04 million | Fiscal year 2012: -$7.91 million | Fiscal year 2011: -$4.62 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: